<DOC>
	<DOCNO>NCT02654483</DOCNO>
	<brief_summary>Itch , pruritus , common complain report patient epidermolysis bullosa ( EB ) subtypes , current effective treatment . Itch often trigger scratch creates new wound increase EB disease severity . This study aim target physiological mechanism pruritus . Substance P major mediator pruritus bind receptor neurokinin-1 ( NK1 ) , expressed central nervous system skin . VPD-737 ( serlopitant ) , drug inhibits NK1 receptor , show reduce severe itch previous study 257 adult patient chronic pruritus . The investigator test VPD-737 14 patient EB Phase II randomize , placebo-controlled , double-blinded clinical trial . Our goal determine whether daily oral administration VPD-737 ( 5 mg ) effective safe adolescent adult EB .</brief_summary>
	<brief_title>Neurokinin-1 Receptor Antagonist Treatment Itch EB Patients</brief_title>
	<detailed_description />
	<mesh_term>Pruritus</mesh_term>
	<mesh_term>Epidermolysis Bullosa</mesh_term>
	<mesh_term>Neurokinin A</mesh_term>
	<mesh_term>Substance P</mesh_term>
	<mesh_term>Neurokinin-1 Receptor Antagonists</mesh_term>
	<criteria>Clinical diagnosis epidermolysis bullosa pruritus Have chronic liver renal disease</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>